Partnership Opportunity to Identify Products for Fentanyl Exposure in Personal Protective Equipment Information Database
2019-02-27 2019-03-28 2019-03-28 2018-10-19 2018-11-09 2019-04-01 2018-11-14 2018-10-19 2019-03-21 2019-03-28
CDC-2018-0085-0012 CDC-2018-0085-0019 CDC-2018-0085-0016 CDC-2018-0085-0002 CDC-2018-0085-0004 CDC-2018-0085-0021 CDC-2018-0085-0005 CDC-2018-0085-0003 CDC-2018-0085-0013 CDC-2018-0085-0017
05:00:00 04:00:00 04:00:00 04:00:00 05:00:00 04:00:00 05:00:00 04:00:00 04:00:00 04:00:00
https://api.regulations.gov/v4/comments/CDC-2018-0085-0012 https://api.regulations.gov/v4/comments/CDC-2018-0085-0019 https://api.regulations.gov/v4/comments/CDC-2018-0085-0016 https://api.regulations.gov/v4/comments/CDC-2018-0085-0002 https://api.regulations.gov/v4/comments/CDC-2018-0085-0004 https://api.regulations.gov/v4/comments/CDC-2018-0085-0021 https://api.regulations.gov/v4/comments/CDC-2018-0085-0005 https://api.regulations.gov/v4/comments/CDC-2018-0085-0003 https://api.regulations.gov/v4/comments/CDC-2018-0085-0013 https://api.regulations.gov/v4/comments/CDC-2018-0085-0017
Jonathan Tom Christopher Todd Jimmy Donald Bill Jean Susan Diane
Bihl Ames Hughes Zuella Vo Rust Godfrey Ublieee Lovasic Redden
For this partnership to be most successful, we need manufacturers who are willing to participate and commit to helping end users find appropriate personal protective products that align with current guidance around fentanyl exposure. The current guidance is unclear, and a small working group of manufactures and stakeholders should convene to provide clarity, especially around dermal protection (gowns and coveralls). The CDC has provided guidance around PPE, however in areas such as respiratory, dermal (gowns and coveralls) and eye/face protection, it is not clear as to which PPE would be most effective related to relevant identified PPE standards. I have heard input from manufactures indicating that there is confusion around risk layering (e.g., multiple layers of risk for each identified user group) and that it would be difficult to translate into a guidance tool. More work needs to be done to simplify the PPE selection and risk identification guidance process.   Blauer Manufacturing Co. is interested in participating in this partnership opportunity.  Blauer is a producer of PPE certified to the NFPA 1994 standard for Classes 3, 3R, and 4.  Consistent with the Interagency Boards (IAB) guidance on fentanyl response, our suits are used by drug interdiction teams that target fentanyl production and milling operations. RPB Safety would be happy to participate from a respiratory protection perspective. CDC-2018-0085; NIOSH-319SAS Safety Corp. is willing to participate Hello,I am submitting on behalf of Draeger as we would like to participate.Regards,Jimmy Vo 3M Personal Safety Division would like to participate. CDC-2018-0085; NIOSH-319    National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention Bolle Safety is willing to participate in this program for PPE for Fentanyl Exposure.   this certainly brings about corruption. if fentanyl is that dangerous, why is it allowed to be used in america. why isnt it simply banned. i think this invites corruption when govt allows private industry to make money off references set for those using fentanyl. better to just ban this pollution toxic chemicals from any use at any time in america. this is an invitation to corruption.shut it down. DuPont, as a PPE supplier, is interested in participating with this partnership and continues to be committed to helping end users find appropriate PPE for protection from the hazards of fentanyl exposure.The currently posted CDC guidance for Fentanyl PPE is not clear.  It is suggested that a small working group of manufacturers and other stakeholders should convene to develop further clarity. This is specifically true for standards that reference dermal protection (gowns and coveralls) and eye/face protection.The current CDC guidance for Fentanyl PPE, especially the PPE grid, needs significant clarification. Directing use of NFPA 1999 and NFPA 1994 certified ensembles is not appropriate for the specific Fentanyl hazards to be addressed.  It is suggested that further work should focus on simplifying the PPE selection and risk identification guidance process. Diane Redden, LION First Responders PPE Inc. Lion is very interested in participating in this conversation. LION believes that it is imperative that a responder wear an appropriate level of an NFPA certified garment for any opioid response. A third party tested ensemble serves to protect the responders in an ever changing threat.  